Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rizatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 0.80 |
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 0.80 |
| ▸ | HTR1A | P08908 | 10/20 | 0.80 |
| ▸ | HTR2C | P28335 | 7/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | HTR5A | P47898 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rizatriptan SCHEMBL4714817 | 1.00 | HTR1A (0.80) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL3002162 | 1.00 | HTR1A (0.80) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL27885182 | 0.91 | HTR1A (0.75) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809854 | 0.91 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809846 | 0.91 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL3462253 | 0.90 | HTR1A (0.85) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL29407208 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL12802834 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL26662 | 0.89 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL2326617 | 0.89 | HTR1A (0.83) | HTR1AHTR2CHTR1DHTR1BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3042 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260069603-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12551489-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12551488-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12544383-B1 | Methods of treating migraines with a combination of a meloxicam and a rizatriptan | AXSOME THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-20260023070-A1 | OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS | UNIV JOHNS HOPKINS (US) | 2026-01-22 | — | — | US | claimed |
| EP-4650374-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Axsome Therapeutics, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250332172-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | claimed |
| EP-3536368-B1 | DRY POWDER INHALER COMPRISING A SEROTONIN RECEPTOR AGONIST AND A DIKETOPIPERAZINE FOR TREATING MIGRAINES | MANNKIND CORP (US) | 2025-09-17 | — | — | EP | claimed |
| US-12357640-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003011205-A2 | ENCAPSULATION PRODUCTS FOR CONTROLLED OR EXTENDED RELEASE | CAPRICORN PHARMA, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| WO-2003011204-A2 | DRUG DELIVERY SYSTEMS | CAPRICORN PHARMA, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020099059-A1 | Combination therapy for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | claimed |
| US-20020044962-A1 | Encapsulation products for controlled or extended release | CHERUKURI S RAO (US) | 2002-04-18 | — | — | US | claimed |
| US-20020044960-A1 | Drug delivery systems | CAPRICORN PHARMA, INC. | 2002-04-18 | — | — | US | claimed |
| WO-2002015899-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| US-20020006440-A1 | Rapid-melt semi-solid compositions, methods of making same and methods of using same | CAPRICORN PHARMA, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2002002081-A1 | RAPID-MELT SEMI-SOLID COMPOSITIONS, METHODS OF MAKING SAME AND METHODS OF USING SAME | CAPRICORN PHARMA, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |